Form 8-K - Current report:
SEC Accession No. 0001193125-25-153471
Filing Date
2025-07-01
Accepted
2025-07-01 08:02:18
Documents
14
Period of Report
2025-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d682251d8k.htm   iXBRL 8-K 29242
2 EX-99.1 d682251dex991.htm EX-99.1 19338
6 GRAPHIC g682251g0701102609160.jpg GRAPHIC 3526
  Complete submission text file 0001193125-25-153471.txt   175142

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrca-20250627.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrca-20250627_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrca-20250627_pre.xml EX-101.PRE 11260
16 EXTRACTED XBRL INSTANCE DOCUMENT d682251d8k_htm.xml XML 3618
Mailing Address 10 NORTH HIGH STREET SUITE 200 WEST CHESTER PA 19380
Business Address 10 NORTH HIGH STREET SUITE 200 WEST CHESTER PA 19380 484-453-3300
Verrica Pharmaceuticals Inc. (Filer) CIK: 0001660334 (see all company filings)

EIN.: 463137900 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38529 | Film No.: 251094199
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)